Abstract 1745P
Background
Treatment abandonment (TA) is a major challenge in cancer care leading to poor outcomes and wastage of resources. Reasons for TA are multi-factorial and country specific. Understanding these complexities is the first step toward developing effective strategies for the prevention of TA. Insights and experiences of healthcare workers (HCWs) can provide valuable information about the factors contributing to TA; hence we conducted a qualitative study to understand the issues.
Methods
The participants were purposively selected, experienced HCWs (N=30) treating cancer patients from high-volume cancer centres nationwide. In-depth interviews (semi-structured, open-ended) were conducted by a person trained and experienced in qualitative interviews to understand the perspectives of HCWs on TA among adult cancer patients. We used the grounded theory approach to thematically analyze the data using inductive analysis.
Results
The HCWs (oncologists=17, nurses=6, psycho-oncologists=3, counselors=4) were selected from 9 states of India representing all geographical regions and working in both private (paid services, N= 14) and government (free services, N=16) sectors. The average duration of the interview was 30 minutes, and the reasons for TA perceived by the HCWs were classified under 6 themes: 1) Socio-demographic, 2) Patient-specific, 3) Clinical, 4) Psychological, 5) Health system related, and 6) Economic factors. Catastrophic health expenditure, direct medical and/or non-medical costs, indirect medical costs, poor socio-economic status, lack of specific knowledge about disease and treatment, poor patient-provider communication, accessibility, psychological distress, and toxicities of treatment were the common reasons for TA cited by the HCWs.
Conclusions
The study is one of the first studies reporting on HCWs’ perspective on TA among cancer patients in India. In addition to well-known socio-economic factors, this study identified important themes such as lacunae in communication and psychological issues (e.g., distress) causing TA. The results of this study will help plan quantitative research into the complex issues of TA and interventions to counter the problem.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
P. Ganesan.
Funding
Indian Council of Medical Research-ICMR, New Delhi, India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1902P - Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
Presenter: Audreylie Lemelin
Session: Poster session 23
1903P - Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
Presenter: Viktor Gruenwald
Session: Poster session 23
1904P - Treatment options and outcome of metastatic renal cell carcinoma patients with brain or bone metastases: A real-world evidence from a German retrospective multi-center analysis
Presenter: Pia Paffenholz
Session: Poster session 23
1905P - Heterogeneity in tertiary lymphoid structures predicts the distinct prognosis and immune microenvironment of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster session 23
1906P - Metastasized non-clear cell renal cell carcinoma: Which entities are dangerous? Results learned from reference pathology of the SuniForecast study
Presenter: Arndt Hartmann
Session: Poster session 23
1907P - Multi-omics mapping positions antigenic myeloid-T cell crosstalk at the core of advanced renal cell carcinoma (aRCC) response to immune checkpoint blockade (ICB)
Presenter: Lisa Kinget
Session: Poster session 23
1908P - Utility of circulating tumor (ct)DNA testing for molecular residual disease (MRD) detection and treatment response monitoring in patients (pts) with renal cell carcinoma (RCC)
Presenter: Michael Smigelski
Session: Poster session 23
1909P - Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
Presenter: Larissa Rainho
Session: Poster session 23
1910P - Evaluation of a genome-wide methylome enrichment platform for circulating tumor DNA quantification and prognostic performance in renal cell carcinoma (RCC)
Presenter: Brian Rini
Session: Poster session 23
1911P - Effect of VHL mutations on efficacy of immune checkpoint inhibitors in renal cell carcinoma
Presenter: Guojie Yu
Session: Poster session 23